Skip to main content
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track ACXP — free
$1.12 +0.09 (+8.74%) Play latest call Q3 2026 earnings call transcript
Market Cap
$6.24M
Shares
6.06M
Volume · Nov 19 131.97K Avg daily vol (3M) 97.86K

Acurx Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Acurx Pharmaceuticals, Inc. (ACXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-12
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2026 Earnings Call Transcript
Confident tone FDA regulatory pathway Pathfinder recurrent CDI trial ASPIRE Phase III program
Diluted EPS
$-0.49
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-10-16
Acurx Pharmaceuticals, Inc. (ACXP) October 16, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-14
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Confident tone ibezapolstat (IBZ) clinical program and efficacy Microbiome and recurrence mechanism Phase III and FDA pathway strategy
Diluted EPS
$-0.62
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-13
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Date not confirmed
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Positive tone Microbiome-Sparing Mechanism / Class Effect Ibezapolstat Phase 3 Funding and Strategy Regulatory Designations and FDA Interactions
Diluted EPS
$-1.23
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Date not confirmed
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Positive tone Ibezapolstat Phase IIb data and Phase III readiness Financing and capital raising Partnerships and government funding
Diluted EPS
$-1.89
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript
Positive tone Microbiome Differentiation and Publications Ibezapolstat Phase 3 Program and Funding Lancet Microbe Publication
Diluted EPS
$-2.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Positive tone Ibezapolstat (IBZ) Phase 3 readiness Clinical data and scientific publications Partnership and government funding pursuit
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Confident tone Ibezapolstat Phase III readiness C. difficile clinical results and anti-recurrence data Intellectual property and patents
Diluted EPS
$-3.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript
Confident tone Ibezapolstat Phase 3 readiness and clinical progress Intellectual property and microbiome patent Financial position and cash runway
Diluted EPS
$-5.21
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
Confident tone Phase 3 readiness and FDA alignment Ibezapolstat clinical and microbiology data Phase 3 cost and funding
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
Confident tone Phase III Clinical Trial Planning Ibezapolstat Phase IIb Clinical Data FDA Regulatory Pathway
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript
Diluted EPS
$-4.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2023 Earnings Call Transcript
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2023 Earnings Call Transcript
Diluted EPS
$-5.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
Diluted EPS
$-6.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2022 Earnings Call Transcript
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2022 Earnings Call Transcript
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-17
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-16
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2021 Earnings Call Transcript
Diluted EPS
$-9.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2021 Earnings Call
Diluted EPS
$-11.40
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 webcasts
Key facts CIK 1736243 CUSIP 00510M203 13F (30d) 20 filings 19 filers Visit website Investor relations